68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah
Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new biomarker
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer
Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New Jersey . | May 5, 2022